AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease
– Topline results expected in November 2022 BALTIMORE, April 21, 2021 — AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD). The clinical trial, known as “HOPE4MCI” (NCT03486938), is a 78-week…